Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SGN-30 (Seattle genetics).

Roland Schnell1, Peter Borchmann

  • 1Department of Internal Medicine I, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany. roland.schnell@uni-koeln.de

Current Opinion in Molecular Therapeutics
|April 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same author

Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma.

Blood advances·2026
Same author

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

HemaSphere·2026
Same author

Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.

Blood advances·2026
Same author

Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers.

Future oncology (London, England)·2026
Same author

Methodological illustration using machine learning methods to predict cancer-related fatigue in cancer patients.

Journal of behavioral medicine·2026

Seattle Genetics is developing SGN-30, a novel antibody therapy targeting CD30. This treatment shows potential for various lymphomas, leukemia, and autoimmune conditions like multiple sclerosis.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Hodgkin's disease and certain non-Hodgkin's lymphomas are significant hematological malignancies.
  • Current treatments for these cancers and immunological diseases have limitations.
  • The CD30 antigen is a promising target for therapeutic intervention.

Purpose of the Study:

  • To evaluate the safety and efficacy of SGN-30, an anti-CD30 monoclonal antibody.
  • To explore the potential of SGN-30 in treating hematological malignancies and immunological disorders.

Main Methods:

  • SGN-30 is an intravenously administered recombinant monoclonal antibody.
  • Phase II clinical trials were conducted in the U.S. and Europe.
  • Patient populations included those with Hodgkin's disease, anaplastic large cell lymphoma, and cutaneous lymphoma.

Related Experiment Videos

Main Results:

  • Phase II trials have been initiated and are ongoing.
  • Preliminary data on safety and efficacy are being collected.
  • The study aims to establish the therapeutic window for SGN-30.

Conclusions:

  • SGN-30 represents a potential new therapeutic option for CD30-expressing malignancies.
  • Further investigation is warranted to confirm its efficacy in immunological diseases.
  • The development of SGN-30 may offer new hope for patients with limited treatment options.